Last $461.63 USD
Change Today +69.47 / 17.71%
Volume 2.8M
ISRG On Other Exchanges
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

intuitive surgical inc (ISRG) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/3/14 - $541.23
52 Week Low
05/9/14 - $346.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

intuitive surgical inc (ISRG) Details

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Its da Vinci surgical system translates a surgeon’s natural hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. The da Vinci surgical system comprise a surgeon’s console, a patient-side cart, a 3-D vision system, da Vinci skills simulator, and Firefly fluorescence imaging product that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general surgery, cardiothoracic, and head and neck surgical procedures. The company also manufactures EndoWrist instruments consisting of forceps, scissors, electrocautery, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures. In addition, it offers da Vinci single-site instruments and accessories that allow da Vinci Si surgical systems to work through a single incision; and EndoWrist One vessel sealer, a wristed single-use instrument intended for bipolar coagulation and mechanical transection of vessels up to 7 mm in anastomoses in general, gynecologic, and urologic surgery; and sells various accessory productsdiameter and tissue bundles that fit in the jaws of the instrument. Further, the company provides EndoWrist Stapler 45 instrument, a wristed stapling instrument intended for resection, transaction, and/or creation of, such as sterile drapes, 3-D stereo endoscopes, camera heads, light guides, and other items that are used in conjunction with the da Vinci surgical system. Intuitive Surgical, Inc. markets its products directly and through distributors in the United States and internationally. The company was founded in 1995 and is headquartered in Sunnyvale, California.

2,792 Employees
Last Reported Date: 02/3/14
Founded in 1995

intuitive surgical inc (ISRG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $560.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $391.4K
Senior Vice President of Scientific Affairs
Total Annual Compensation: $380.0K
Chief Compliance Officer, Senior Vice Preside...
Total Annual Compensation: $365.7K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $227.6K
Compensation as of Fiscal Year 2013.

intuitive surgical inc (ISRG) Key Developments

Intuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year 2014

Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of USD 512.2 million against USD 578.5 million a year ago. Income from operations was USD 143 million against USD 218.5 million a year ago. Income before taxes was USD 142.6 million against USD 222.8 million a year ago. Net income was USD 104 million or USD 2.77 per diluted share against USD 159.1 million or USD 3.90 per diluted share a year ago. Non-GAAP revenue was USD 506.5 million against USD 578.5 million a year ago. Non-GAAP income from operations was USD 195.8 million against USD 262.9 million a year ago. Non-GAAP net income was USD 140.2 million or USD 3.73 per diluted share against USD 189 million or USD 4.63 per diluted share a year ago. The decrease in revenue relative to the second quarter of 2013 reflected lower stocking orders associated with fewer system sales. The increase relative to the first quarter reflects increased procedures and number of stocking orders associated with higher systems placed, partially offset by customer buying patterns and fewer sales of energy-generator units and Single-Site starter kits. For the six months, the company reported total revenue of USD 976.9 million against USD 1,189.9 million a year ago. Income from operations was USD 199.6 million against USD 469.7 million a year ago. Income before taxes was USD 203.1 against USD 478.3 million a year ago. Net income was USD 148.3 million or USD 3.87 per diluted share against USD 348 million or USD 8.47 per diluted share a year ago. Non-GAAP revenue was USD 966.8 million against USD 1,189.9 million a year ago. Non-GAAP income from operations was USD 384.8 million against USD 557.9 million a year ago. Non-GAAP net income was USD 278.7 million or USD 7.28 per diluted share against USD 407.5 million or USD 9.91 per diluted share a year ago. For the year 2014, the company expects gross profit margin to be to move differentially lower, based upon the impact of new products, product mix and market conditions. Actual gross profit margin will vary quarter-to-quarter, depending largely upon product mix and systems production volume. The company expects to grow operating expenses roughly 10% to 13% above the 2013 levels. The company expects income tax rate to be between 25% and 28% pretax income, depending primarily on the mix of U.S. and international profits.

Intuitive Surgical and Adachi Co. Ltd. Announce an Agreement to Transition Japanese Sales, Marketing, Service, Support and Training for da Vinci(R) Systems

Intuitive Surgical and Adachi Co. Ltd. announced an agreement to transition Japanese sales, marketing, service, support and training for da Vinci(R) Systems, instruments and accessories to Intuitive Surgical, a transition that began June 26, 2014. With this agreement, Intuitive Surgical will further expand its presence in the Asia Pacific region. Intuitive Surgical and Adachi will work together to ensure da Vinci customers in Japan experience a smooth transition. In addition, Intuitive Surgical will offer employment to a number of Adachi employees who have experience with the da Vinci business. These employees will be added to Intuitive Surgical's existing regulatory team, call center and other departments to further strengthen the highly capable organization. The terms of the arrangement were not disclosed and are not expected to have a material impact on Intuitive Surgical's results of operations.

Intuitive Surgical, Inc. Receives CE Mark for its da Vinci Xi Surgical System

Intuitive Surgical, Inc. announced it has received a CE Mark for its da Vinci Xi Surgical System. Achieving this milestone allows the company to market the Xi System in Europe and other countries that require the CE Mark. In April, the da Vinci Xi System received clearance from the U.S. Food and Drug Administration (FDA) and is now commercialized in the United States. The da Vinci Xi System is intended to be a technological leap forward in replacing large-incision open surgeries with a minimally invasive approach. Intuitive Surgical designed the new da Vinci Xi System to optimize ease-of-use. With the U.S. and European introductions underway, Intuitive Surgical is seeking additional regulatory clearances to market the da Vinci Xi System around the world. These include clearances for advanced technologies such as vessel sealing, stapling and fluorescence imaging, which are designed to enhance the capabilities of the da Vinci Xi System. This month, Intuitive Surgical received the first of these clearances from the FDA to market the EndoWrist(r) One(tm) Vessel Sealer instrument for the da Vinci Xi System in the United States. Vinci Xi System expands upon the core da Vinci System features, which include wristed instruments, 3D-HD visualization, intuitive motion and an ergonomic design. As with all da Vinci Surgical Systems, the da Vinci Xi System's immersive 3D-HD vision system provides surgeons with a highly magnified view, virtually extending their eyes and hands into the patient. Compared with prior da Vinci Systems, the da Vinci Xi System's key features include: A new overhead instrument arm architecture designed to facilitate anatomical access from virtually any position; A new endoscope digital architecture that creates a simpler, more compact design with improved visual definition and clarity; An ability to attach the endoscope to any arm, providing flexibility for visualizing the surgical site; Smaller, thinner arms with newly designed joints that offer a greater range of motion than ever before; and Longer instrument shafts designed to give surgeons greater operative reach. The da Vinci Xi System is an expandable technology platform that is designed to accommodate and seamlessly integrate a range of current technologies in areas such as fluorescence imaging, advanced instruments and anatomical access, as well as future innovations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISRG:US $461.63 USD +69.47

ISRG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerner Corp $55.97 USD +1.62
CR Bard Inc $145.83 USD +2.01
Edwards Lifesciences Corp $85.54 USD -0.16
Endo International PLC $70.27 USD +0.70
Mettler-Toledo International Inc $259.01 USD -3.24
View Industry Companies

Industry Analysis


Industry Average

Valuation ISRG Industry Range
Price/Earnings 29.4x
Price/Sales 7.1x
Price/Book 4.1x
Price/Cash Flow 28.6x
TEV/Sales 6.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTUITIVE SURGICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at